scholarly journals COVID-19 Serology in New York State Using a Multiplex Microsphere Immunoassay

2021 ◽  
Author(s):  
Danielle T. Hunt ◽  
Jennifer L. Yates ◽  
Karen E. Kulas ◽  
Kyle Carson ◽  
Theresa Lamson ◽  
...  
Keyword(s):  
New York ◽  
New York State ◽  
Fine Tuning ◽  
Target Antigen ◽  
Protein Antigens ◽  
Serological Tests ◽  
York State ◽  
Global Pandemic ◽  
Human Coronaviruses ◽  
Microsphere Immunoassay

The emergence of SARS-CoV-2, leading to COVID-19, necessitated the development of new molecular and serological tests. Here, we describe a multiplexed serological assay developed as the global pandemic moved into New York State in the spring of 2020. The original microsphere immunoassay used a target antigen from the SARS-CoV-1 virus responsible for the 2003 SARS outbreak, but evolved to incorporate multiple SARS-CoV-2 protein antigens (nucleocapsid, spike and spike domains, spike and nucleocapsid proteins from seasonal human coronaviruses). Besides being highly versatile due to multiplex capabilities, the assay was highly specific and sensitive and adaptable to measuring both total antibodies and antibody isotypes. While determining the assay performance characteristics, we were able to identify antibody production patterns (e.g., kinetics of isotypes, individual variations) for total antibodies and individual antibody classes. Overall, the results provide insights into the laboratory response to new serology needs, and how the evolution and fine-tuning of a serology assay helped contribute to a better understanding of the antibody response to SARS-CoV-2.

scholarly journals Deaths from Covid-19: Who are the forgotten victims?

2020 ◽  
Author(s):  
Kieran F. Docherty ◽  
Jawad H Butt ◽  
Rudolf A. de Boer ◽  
Pooja Dewan ◽  
Lars Køber ◽  
...  
Keyword(s):  
New York ◽  
The Netherlands ◽  
New York State ◽  
Population Based ◽  
Clinical Activity ◽  
National Agency ◽  
England And Wales ◽  
York State ◽  
Global Pandemic ◽  
Excess Deaths

AbstractBackgroundWith the spreading global pandemic of coronavirus disease 2019 (Covid-19) there has been disruption to normal clinical activity in response to the increased demand on health services. There are reports of a reduction in non-Covid-19 emergency presentations. Consequentially, there are concerns that deaths from non-Covid-19 causes could increase. We examined recent reported population-based mortality rates, compared with expected rates, and compared any excess in deaths with the number of deaths attributed to Covid-19.MethodsNational agency and death registration reports were searched for numbers of deaths attributed to Covid-19 and overall mortality that had been publicly reported by 22 April 2020. Data on the number of deaths attributed to Covid-19, the total number of deaths registered in the population and the historical average over at least 3 years were collected. Data were available for 3 Northern European countries (England & Wales, Scotland and the Netherlands) and New York State, United States of America.FindingsThere was an increase in observed, compared with expected, mortality in Scotland (+73%), England and Wales (+49%), the Netherlands (+65%) and New York state (+34%). Of these deaths, only 65% in Scotland, 68 % in England and Wales, 49% in the Netherlands and 73% in New York state were attributed to Covid-19 leaving a number of excess deaths not attributed to Covid-19.InterpretationA substantial proportion of excess deaths observed during the current COVID-19 pandemic are not attributed to COVID-19 and may represent an excess of deaths due to other causes.FundingNone

New York State Assisted Outpatient Treatment Program Evaluation

2009 ◽  
Author(s):  
Marvin S. Swartz ◽  
Jeffrey W. Swanson ◽  
Henry J. Steadman ◽  
Pamela Clark Robbins ◽  
John Monahan
Keyword(s):  
New York ◽  
Program Evaluation ◽  
Treatment Program ◽  
Outpatient Treatment ◽  
New York State ◽  
York State ◽  
Assisted Outpatient Treatment
Sign in / Sign up

Export Citation Format

Share Document